The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.
Ricciuti, B., Genova, C., Bassanelli, M., De Giglio, A., Brambilla, M., Metro, G., et al. (2019). Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression. CLINICAL LUNG CANCER, 20(3), 178-185 [10.1016/j.cllc.2019.02.001].
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression
Ricciuti B.;De Giglio A.;
2019
Abstract
The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
